A national registry to assess the value of cardiovascular magnetic resonance imaging after primary percutaneous coronary intervention pathway activation: a feasibility cohort study

Jessica M Harris,1 Rachel C Brierley,1 Maria Pufulete,1 Chiara Bucciarelli-Ducci,2 Elizabeth A Stokes,3 John P Greenwood,4 Stephen H Dorman,2 Richard A Anderson,5 Chris A Rogers,1 Sarah Wordsworth,3 Sunita Berry6 and Barnaby C Reeves1*

1Clinical Trials and Evaluation Unit, Bristol Trials Centre, University of Bristol, Bristol, UK
2National Institute for Health Research (NIHR) Bristol Cardiovascular Research Unit, Bristol Heart Institute, University of Bristol, Bristol, UK
3Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK
4Multidisciplinary Cardiovascular Research Centre and Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
5University Hospitals of Wales, Cardiff, UK
6NHS England, South West Clinical Networks and Senate, Bristol, UK

*Corresponding author barney.reeves@bristol.ac.uk

Declared competing interests of authors: Chiara Bucciarelli-Ducci has received personal fees from Circle Cardiovascular Imaging (Calgary, AB, Canada). Chris A Rogers is a member of the Health Technology Assessment (HTA) Commissioning Board. Barnaby C Reeves reports former membership of the HTA Commissioning Board (from January 2012 to 31 March 2016) and the HTA Efficient Study Designs Board (October–December 2014). He also reports current membership of the HTA Interventional Procedures Methods Group and Systematic Reviews Programme Advisory Group (Systematic Reviews National Institute for Health Research Cochrane Incentive Awards and Systematic Review Advisory Group).

Published July 2019
DOI: 10.3310/hsdr07240
Scientific summary

National registry for CMR after PPCI pathway activation
Health Services and Delivery Research 2019; Vol. 7: No. 24
DOI: 10.3310/hsdr07240

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Cardiovascular magnetic resonance (CMR) is a non-invasive imaging technique that assesses heart structure and function with high spatial and temporal resolution. The use of CMR has increased in all subgroups of acute coronary syndrome (ACS) patients, including those who activate the primary percutaneous coronary intervention (PPCI) pathway. It is unknown if undergoing CMR influences patient management or reduces the length of hospital stay or the risk of major adverse cardiovascular events (MACEs) in these patients.

Objectives

- To determine whether or not it is feasible to set up a national registry linking routinely collected data from hospital information systems (HISs) for the index event (emergency angiography with or without PPCI) with hospital episode data [from Hospital Episode Statistics (HES) and Patient Episode Database Wales (PEDW), which collects equivalent information for the NHS Wales hospitals] and death registration data [from the Office for National Statistics (ONS)] for follow-up in the 12 months after the index event, in order to investigate the role of CMR in patients who activate the PPCI pathway.
- To describe resource use and associated costs of having CMR and to identify key drivers of cost-effectiveness for CMR.
- To identify an outcome measure representing a definitive change in clinical management, conditional on having undergone CMR, that would be credible to cardiologists and other stakeholders as an interim measure of the ‘value added’ by doing CMR.

Design

The study included three components to address the objectives listed in the preceding section:

1. Feasibility prospective cohort study – we established if we could implement patient consent, extract data about the index event from multiple HISs and link these data with hospital episode data for follow-up. We also quantified the proportion of patients who undergo CMR. We explored whether or not the cohort study could be set up using only hospital episode data.
2. Simple cost-effectiveness models – we developed economic decision models in two subgroups of patients who activate the PPCI pathway: (1) patients with multivessel disease and (2) patients with unobstructed coronary arteries. These subgroups were identified in the protocol (before commencing work on the study) as having the potential to benefit from CMR.
3. Formal consensus study – we defined important changes in management resulting from CMR and subgroups of patients to whom these changes relate. Potential changes in management were described from literature review and cardiologist expert opinion and were reviewed by a consensus panel and additional cardiologists (from across the UK). We determined whether or not changes in management defined as being important by formal consensus could be identified in hospital episode data in the 12 months following the index event, with the intention to formulate an ‘interim’ outcome measure representing a definitive change in clinical management that could be used for a future registry.
Setting

- Feasibility prospective cohort study: four 24/7 PPCI hospitals in England and Wales (two with and two without a dedicated CMR facility, both representing usual care in the NHS).
- Cost-effectiveness models: usual care (with or without CMR) in the NHS.
- Formal consensus study: secondary care (cardiology departments) across the UK.

Study population

Feasibility prospective cohort study
This comprised patients who activated the PPCI pathway and underwent an emergency coronary angiogram whether or not they received PPCI. We included patients if they were aged ≥18 years and underwent an emergency angiogram, defined as taking place within 2 hours of arrival at the hospital, unless specified otherwise by local protocols. We excluded patients if they were prisoners or lacked mental capacity to consent.

Cost-effectiveness models

- Model 1 (multivessel disease): patients who activate the PPCI pathway, have their index angiography and PPCI and are identified as having multivessel disease (commonly defined as stenosis of >50% from the angiogram) in two or more coronary arteries.
- Model 2 (unobstructed coronary arteries): patients who activated the PPCI pathway, had their index angiography and were found to have unobstructed coronary arteries.

Formal consensus study
This comprised consultant cardiologists with CMR, interventional, echocardiography (ECHO), electrophysiology and heart failure expertise from across the UK.

Intervention(s)

Feasibility prospective cohort study
Cardiovascular magnetic resonance performed/not performed within 10 weeks of the index event (whether during the index admission or subsequently as an outpatient). All patients were assumed to receive standard ECHO as part of usual care.

Cost-effectiveness models

- Model 1 (multivessel disease): three different ischaemia testing methods; CMR versus stress ECHO versus pressure wire.

Formal consensus study
For each statement, CMR was considered alongside standard or stress ECHO as appropriate.

Main outcome measures

Feasibility prospective cohort study

- Patient consent implemented at all four hospitals.
- Data linkage and extraction from multiple local HISs achieved for >90% of consented patients at all four hospitals.
- Local data successfully linked with hospital episode data for >90% of consented patients at all four hospitals.
CMR requested and carried out for ≥ 10% of patients activating the PPCI pathway in CMR hospitals.

Whether or not the registry could be compiled from hospital episode data rather than from multiple HISs.

Cost-effectiveness model
The main outcomes were key drivers of cost-effectiveness for CMR in patients with (1) multivessel disease (model 1) and (2) unobstructed coronary arteries (model 2).

Formal consensus study
- Identification, through formal consensus, of the important changes in management resulting from CMR and the subgroups of patients to whom these changes relate.
- Identification of relevant subgroups of patients in the data sets obtained (local HISs and follow-up hospital episode data).
- Ascertainment of the consequences of important changes in management from hospital episode data.

Data sources

Feasibility prospective cohort study
- Index procedure: local HIS at each participating hospital –
  - basic demography [local Patient Administration System (PAS)/British Cardiovascular Intervention Society – Central Cardiac Audit Database (BCIS-CCAD)]
  - clinical characteristics on presentation at the index admission, peri- and post-procedural (PPCI) characteristics (local catheter laboratory database/BCIS-CCAD)
  - ECHO and CMR reports (local imaging databases)
  - biochemistry (local biochemistry databases)
  - medications on discharge (one hospital only).
- Follow-up: hospital episode data. We requested inpatient, outpatient, accident and emergency and critical care data sets.

Cost-effectiveness models
Data were sourced from a literature review for model parameter estimates and NHS Reference Costs (Department of Health and Social Care. NHS Reference Costs 2015 to 2016. London: Department of Health and Social Care; 2016) for unit costs.

Formal consensus study
For the formal consensus study, data were sourced from a literature review and cardiologist expert opinion. In-hospital data were sourced from local HIS data and follow-up data were sourced from HES data.

Results

Feasibility prospective cohort study
- Consent using conventional methods was successfully implemented (across all hospitals, consent rates were 59–74%); 2462 patients were screened (May 2013–September 2014) but only 1670 participants (68%) were recruited.
- Hospitals submitted varying numbers of requested data: clinical data (for ≥ 82% of patients across all hospitals), biochemistry data (three hospitals, for ≥ 98% of patients), ECHO data (three hospitals, for 34–87% of patients) and medications data (for 97% of patients in one hospital). Imaging data (ECHO and CMR data from one hospital) were submitted as free-text reports extracted from radiology databases.
HIS data were linked with hospital episode data for 99% of all consented patients. We identified an admission that matched the index admission within ± 1 day for 93% and 97% of consented patients. At the two CMR hospitals, 14% and 20% of patients received CMR. We identified 98% of patients who underwent PPCI and 85% of patients who had an emergency angiogram but no PCI in hospital episode data. We could identify CMR exposure in hospital episode data for only 29% (55/189) of patients who had a CMR in our cohort.

Cost-effectiveness models

In both model 1 (multivessel disease) and model 2 (unobstructed coronary arteries), the difference in quality-adjusted life-years (QALYs) between CMR and no CMR was very small (0.0012, 95% CI –0.0076 to 0.0093 and 0.0005, 95% CI –0.0050 and 0.0077, respectively) (the ‘current’ comparator for model 1 is stress ECHO; the ‘current’ comparator for model 2 is standard ECHO). The diagnostic accuracy of the ischaemia tests was the key driver of cost-effectiveness in sensitivity analyses for both model 1 and model 2.

Formal consensus study

There was consensus that CMR leads to clinically important changes in management in five patient subgroups, namely those with: (1) out-of-hospital cardiac arrest, (2) unobstructed coronary arteries, (3) left ventricular (LV) thrombus, (4) multivessel disease and (5) PPCI with CMR markers indicating poor prognosis. Patients with unobstructed arteries and PPCI patients could be identified from both the local HIS data set and hospital episode data. Patients with an out-of-hospital cardiac arrest and PPCI patients who developed a LV thrombus could not be identified from the local HIS data set, but could be identified in hospital episode data. Patients with multivessel disease could be identified only from the local HIS data set, not from hospital episode data.

We identified the following changes in management in hospital episode data: new diagnoses and procedures (those that resulted in hospital admission and were recorded in outpatient visits) and the frequency of outpatient appointments related to cardiac events. We could not identify changes in medications because there were no medication data in the hospital episode data.

Limitations

Feasibility prospective cohort study

We could not identify all eligible patients from local HISs. The conventional consent model failed to capture a sizeable proportion of the eligible population, but we could not identify and test a more efficient model of obtaining consent. The study population did not include patients presenting with a broader diagnosis of ACS but not requiring emergency coronary angiography (e.g. those with non-ST elevation myocardial infarction), who may also benefit from CMR. The study took longer than anticipated to complete after the end of recruitment because our application for hospital episode data coincided with the moratorium on all data requests imposed by NHS Digital (formerly known as the Health and Social Care Information Centre). During this time, data availability/quality is likely to have changed/improved given the rapidly evolving NHS information technology (IT) systems/platforms. New diagnostic tests for detecting ischaemia (e.g. pressure wire), directly competing with CMR, were also introduced during the time frame of the study and were rapidly adopted by many cardiologists. These changes to usual care weakened the importance of the research question that we described at the outset – the comparison of CMR versus standard ECHO/stress ECHO (usual care at the start of the study) – but highlighted the importance of different research questions.
Cost-effectiveness models
There is uncertainty around the majority of parameter estimates in both models. Many estimates were based on single studies with small sample sizes. Some of these studies were conducted outside the UK, where patient pathways differ. In the base-case analyses, CMR and pressure wire were treated as reference standards and both were assumed to have 100% sensitivity and specificity. This assumption may not be true and, if not, this will influence findings because the diagnostic accuracy of the ischaemia tests was found to be the key driver of cost-effectiveness.

Individual patient data on resource use from hospital episode data were not available in time to be used in the cost-effectiveness analyses. Therefore, we estimated resource use associated with each of the patient pathways, so, although the standard care pathways have been costed, it is likely that we have underestimated the variability between individual patients and their actual patient pathways. Finally, there was also uncertainty about the utility estimates used in the cost-effectiveness models because we did not find good-quality primary data.

Formal consensus study
The number of panel members in our expert panel was lower than the recommended 8–12 members for a consensus panel. We extended the survey to other UK cardiologists to compensate for this and prevent the possibility of introducing bias (given the self-selected nature of the panel). We did not include different stakeholder groups in the consensus panel because the technical wording of the statements would not have been easily understood by non-cardiologists. Therefore, we cannot be certain that the changes in management that were identified are relevant to other stakeholders (e.g. commissioners and patients).

Conclusions

Cost-effectiveness models
For each of the base-case models, the differences in QALYs between strategies were very small; therefore, the results were largely driven by the differences in costs, although these were also modest. Sensitivity analyses around the two models identified the diagnostic accuracy of the ischaemia tests as the key driver of cost-effectiveness.

Formal consensus study
We defined five subgroups of patients who activate the PPCI pathway for whom there was consensus that CMR changes patient management in a clinically important way. All subgroups could be identified in either the local HIS data set, hospital episode data or both. Some, but not all, important changes in management could be identified in follow-up HES/PEDW data. The main constraints on identifying important changes in management were (1) outpatient hospital episode data were poorly coded with respect to the diagnosis, (2) medication data were not available at baseline or follow-up (preventing inspection of/prescription of changes in medication after the index event) and (3) data about diagnostic investigations were poorly coded in both acute care and outpatient data sets.
Future work

- Identify/test a more efficient method of obtaining consent.
- Some limitations of our study are now historic and others are being addressed. Therefore, it is recommended to test the feasibility of conducting the study using national data sets [HES/BCIS/ Diagnostic Imaging Dataset (DID), Clinical Practice Research Datalink (CPRD) for medications], which are likely to be able to capture all of the eligible population, without the need for individual patient consent; MACEs could be used as the outcome.
- Cost-effectiveness models suggest that it is important for the NHS to have a definitive answer about the relative diagnostic accuracy of CMR versus pressure wire, despite the fact that the pressure wire is rapidly superseding CMR across catheter laboratories.
- A feasible registry is a goal worth pursuing, offering a test bed for the rapid evaluation of changes in practice in this expensive and fast-moving area of clinical care (often driven by commercial interest).

Funding

Funding for this study was provided by the Health Services and Delivery Research programme of the National Institute for Health Research (NIHR). This study was designed and delivered in collaboration with the Clinical Trials and Evaluation Unit, a UK Clinical Research Collaboration-registered clinical trials unit that, as part of the Bristol Trials Centre, is in receipt of NIHR clinical trials unit support funding.
Criteria for inclusion in the Health Services and Delivery Research journal

Reports are published in Health Services and Delivery Research (HS&DR) if (1) they have resulted from work for the HS&DR programme or programmes which preceded the HS&DR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

HS&DR programme

The Health Services and Delivery Research (HS&DR) programme, part of the National Institute for Health Research (NIHR), was established to fund a broad range of research. It combines the strengths and contributions of two previous NIHR research programmes: the Health Services Research (HSR) programme and the Service Delivery and Organisation (SDO) programme, which were merged in January 2012.

The HS&DR programme aims to produce rigorous and relevant evidence on the quality, access and organisation of health services including costs and outcomes, as well as research on implementation. The programme will enhance the strategic focus on research that matters to the NHS and is keen to support ambitious evaluative research to improve health services.

For more information about the HS&DR programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hsdr

This report

The research reported in this issue of the journal was funded by the HS&DR programme or one of its preceding programmes as project number 11/2003/58. The contractual start date was in January 2013. The final report began editorial review in October 2017 and was accepted for publication in July 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HS&DR editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HS&DR programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HS&DR programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2019. This work was produced by Harris et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Honorary Professor, University of Manchester, and Senior Clinical Researcher and Associate Professor, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Director, NIHR Dissemination Centre, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk